Moonlake Immunotherapeutics

Biotechnology • Healthcare • Zug, Switzerland • MLTX (NCM)

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3% - Time to Sell? - MarketBeat

MarketBeat • Jan 2

MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment - Investor's Business Daily

Investor's Business Daily • Sep 29

MoonLake Immunotherapeutics Stock: Ignore The Panic, Catch The Upside (NASDAQ:MLTX) - Seeking Alpha

Seeking Alpha • Nov 18

MoonLake's stock crashes after high placebo rate eclipses IL-17 drug's phase 3 readouts - Fierce Biotech

Fierce Biotech • Sep 29

MoonLake Immunotherapeutics (MLTX) Q2 Net Loss Widens to US$55 Million - Yahoo Finance

Yahoo Finance • Sep 13

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has MoonLake Immunotherapeutics had layoffs?

No layoff events have been recorded for MoonLake Immunotherapeutics in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does MoonLake Immunotherapeutics have?

MoonLake Immunotherapeutics has approximately 100 employees.

What industry is MoonLake Immunotherapeutics in?

MoonLake Immunotherapeutics operates in the Biotechnology industry, within the Healthcare sector.

Is MoonLake Immunotherapeutics a publicly traded company?

Yes, MoonLake Immunotherapeutics is publicly traded under the ticker symbol MLTX on the NCM. The company has a market capitalization of approximately $0.98 billion.

Where is MoonLake Immunotherapeutics headquartered?

MoonLake Immunotherapeutics is headquartered in Zug, Switzerland.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.